Document is current

Article History

Received: 7 June 2024

Accepted: 12 January 2025

First Online: 27 February 2025

Declarations

:

: FP and PF do not have conflict of interest to disclose. LN, PF, StS, JL, LU, FB, JR, JSL, RCE, KM are full time employees at Fresenius Medical Care. This study was supported by a research grant from Fresenius Medical Care. Bellocchio F., Casana Eslava R., Llopis Silvestre J., Morillo Navarro K., Ferraresi P., Usvyat L., Larkin J., Rosemberg J., Stuard S., Neri L. are full time employees at Fresenius Medical Care. Len Usvyat, John Larkin report share options/ownership in Fresenius Medical Care and being an inventor on patents in the field of dialysis. Len Usvyat reports being an advisory board member for Privacy Analytics Inc. John Larkin reports receipt of honorarium from The Lancet, being on the Editorial Board of Frontiers in Physiology and Frontiers in Medicine, Nephrology, and being a chair person for the MONitoring Dialysis Outcomes (MONDO) Initiative study group and serving on the MONDO Steering Committee. PROGRES-CKD is proprietary of Fresenius Medical Care and it is not yet available for clinical use. It is available to researchers and academic institutions based on research collaboration agreements with Fresenius Medical Care.

: The analysis has been conducted in accordance with the declaration of Helsinki. The Ethical Committee of the San Gerardo Hospital/IRCCS San Gerardo dei Tintori, approved the study protocol on 21–11-2022 (Protocol Code: PROGRES-CKD).

: As per the protocol approved by the Ethical Committee, given the retrospective nature of the study, the minimal risk involved in the study, the study conduct did not violate the rights and autonomy of the patients, and because the research could not have been conducted otherwise, informed consent was waived.